Takeda Announces Creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program

A Five-year Commitment From Takeda Will Help Children’s National Launch a First-of-its-Kind Rare Disease Clinical Protocol Program

WASHINGTON, DC and CAMBRIDGE, MA, March 1, 2021 — Children’s National Hospital and Takeda Pharmaceutical Company Limited (“Takeda”) announced the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.

Rare-CAP will be led by the Rare Disease Institute at the new Children’s National Research & Innovation Campus that opened in February 2021 on the grounds of the former Walter Reed Army Medical Center. Read the full press release.

Stay in Touch with NGF

Learn about the latest research, news and events.